CRISPR Therapeutics AG
CRSP43.204USD
+1.623+3.90%
시장 운영 시간 （ET）시세는 15분 지연됩니다
3.73B시가총액
손실P/E TTM
자세한 내용은 CRISPR Therapeutics AG 회사
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
회사 정보
종목 코드 CRSP
회사 이름CRISPR Therapeutics AG
상장일Oct 19, 2016
설립일2013
CEODr. Samarth Kulkarni, Ph.D.
직원 수393
유형Ordinary Share
회계 연도 종료Oct 19
주소Baarerstrasse 14
도시ZUG
증권 거래소NASDAQ Global Market Consolidated
국가Switzerland
우편 번호6300
전화41415613279
웹사이트https://crisprtx.com/
종목 코드 CRSP
상장일Oct 19, 2016
설립일2013
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
280.71K
+18.70%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Tue, May 20
마지막 업데이트: Tue, May 20
주주
주주 유형
주주
주주
비율
ARK Investment Management LLC
11.77%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Nikko Asset Management Co., Ltd.
2.94%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.92%
주주
주주
비율
ARK Investment Management LLC
11.77%
Capital International Investors
7.03%
T. Rowe Price Investment Management, Inc.
4.40%
Nikko Asset Management Co., Ltd.
2.94%
Nikko Asset Management Americas, Inc.
2.94%
Other
70.92%
주주 유형
주주
비율
Investment Advisor
41.25%
Investment Advisor/Hedge Fund
20.51%
Hedge Fund
5.55%
Research Firm
4.15%
Venture Capital
3.64%
Individual Investor
1.69%
Bank and Trust
0.73%
Sovereign Wealth Fund
0.51%
Pension Fund
0.39%
Other
21.57%
기관 주식 보유
마지막 업데이트: Mon, Feb 24
마지막 업데이트: Mon, Feb 24
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
934
69.16M
80.09%
-72.64K
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
2023Q1
1053
55.90M
70.89%
-6.49M
2022Q4
1074
54.64M
69.81%
-8.49M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
ARK Investment Management LLC
8.97M
10.46%
-149.43K
-1.64%
Dec 31, 2024
Capital International Investors
8.74M
10.19%
+816.79K
+10.30%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
3.81M
4.44%
+1.07M
+39.24%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
2.75M
3.2%
-222.36K
-7.49%
Dec 31, 2024
Nikko Asset Management Americas, Inc.
2.75M
3.2%
-221.54K
-7.47%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
2.51M
2.93%
+87.43K
+3.60%
Dec 31, 2024
State Street Global Advisors (US)
2.49M
2.9%
-501.46K
-16.75%
Dec 31, 2024
Fidelity Management & Research Company LLC
2.22M
2.59%
-152.87K
-6.43%
Dec 31, 2024
The Vanguard Group, Inc.
1.72M
2%
+8.83K
+0.52%
Dec 31, 2024
더 보기
관련 ETF
마지막 업데이트: Fri, Jun 6
마지막 업데이트: Fri, Jun 6
이름
비율
ARK Genomic Revolution ETF
7.73%
ARK Innovation ETF
5.02%
Global X Genomics & Biotechnology ETF
3.5%
AXS Green Alpha ETF
3.22%
WisdomTree BioRevolution Fund
1.95%
Virtus LifeSci Biotech Products ETF
1.39%
SPDR S&P Biotech ETF
1.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.78%
Main Thematic Innovation ETF
0.56%
Invesco Nasdaq Biotechnology ETF
0.33%
더 보기
ARK Genomic Revolution ETF
비율7.73%
ARK Innovation ETF
비율5.02%
Global X Genomics & Biotechnology ETF
비율3.5%
AXS Green Alpha ETF
비율3.22%
WisdomTree BioRevolution Fund
비율1.95%
Virtus LifeSci Biotech Products ETF
비율1.39%
SPDR S&P Biotech ETF
비율1.19%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.78%
Main Thematic Innovation ETF
비율0.56%
Invesco Nasdaq Biotechnology ETF
비율0.33%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
